|
|
|
|
| We’re striving to deliver mRNA-LNPs beyond the liver. This Live explores how the industry is advancing tissue targeting, from optimizing lipid formulations to adopting active delivery using ligands and antibodies. We’ll also highlight emerging academic innovations that aim to improve LNP design, quality, and deliverability across diverse cell and tissue types. Join experts discussing challenges, opportunities, and future directions shaping next-generation mRNA therapeutics and translational research efforts worldwide. Register Today! |
|
|
|
|
By Anna Rose Welch, Editorial & Community Director, Advancing RNA | Here, in part one of this multi-part series, we start by examining several of the overall market trends that took shape in 2025. In particular, we hear from Melissa Bonner, CSO of nChroma Bio, Allan Shaw, CFO of CREATE Medicines (formerly Myeloid Therapeutics), and Andy Geall, CDO of Replicate Biosciences, each of whom called out several defining characteristics that set the stage for the important work we have before us in 2026. | |
|
|
Rethinking The "3:1 Rule" In LNP Production | By Cedric Devos, Aniket Udepurkar, and Peter Sagmeister, Postdoctoral Associates, MIT | A new two-step, ideal-mixing strategy from MIT researchers shows how operating briefly in unstable regions of LNP assembly can unlock precise control of particle size and shape—advancing next-gen RNA manufacturing. |
|
|
mRNA Raw Material Pulse Check: Where Innovation Is Hottest | By Advancing RNA Live | The mRNA supply chain is undergoing massive growth in three particular areas. Here, speakers Khaled Yamout & Francoise Ribes walk us through the materials that have undergone the most scientific growth over the past few years and the impacts they’re noting these advancements having on the development of our mRNA drug substances and mRNA-LNP drug products. |
|
|
|
|
|
|
|
| Innovating Autoimmune Treatment With In Vivo CAR-T | Podcast | Novotech | In vivo CAR-T technology is opening new therapeutic frontiers for autoimmune disorders. Listen to what the field must accomplish to convert early scientific promise into meaningful patient outcomes. |
|
|
|
|
|
|
|
|
|
|
|
.png){kind=logo}
